Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE3.2950
- TODAY'S CHANGE (%)0.0350 (1.0736%)
- Bid / Lots3.2900/ 6
- Ask / Lots3.3000/ 2
- Open / Previous Close3.2500 / 3.2600
- Day Range
- 52 Week Range
- Volume73,026
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 1288 | 3.26 |
| 09:38 ET | 100 | 3.27 |
| 09:39 ET | 100 | 3.27 |
| 09:41 ET | 10500 | 3.24 |
| 09:43 ET | 100 | 3.26 |
| 09:45 ET | 1800 | 3.27 |
| 09:50 ET | 900 | 3.265 |
| 09:52 ET | 100 | 3.262 |
| 09:54 ET | 1200 | 3.27 |
| 09:56 ET | 100 | 3.27 |
| 09:57 ET | 1300 | 3.2775 |
| 09:59 ET | 17277 | 3.31 |
| 10:01 ET | 900 | 3.31 |
| 10:03 ET | 7615 | 3.2935 |
| 10:06 ET | 100 | 3.3099 |
| 10:14 ET | 1104 | 3.3 |
| 10:15 ET | 810 | 3.305 |
| 10:19 ET | 3599 | 3.3 |
| 10:21 ET | 600 | 3.3 |
| 10:24 ET | 1930 | 3.3 |
| 10:26 ET | 11002 | 3.3 |
| 10:28 ET | 5775 | 3.29 |
May 16, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 11:16AM ET on Thursday May 16, 2024 by Dow Jones
11:16AM ET on Thursday May 16, 2024 by Dow JonesDJ Mereo BioPharma Group Price Target Maintained With a $6.00/Share by Needham, from 7:33AM ET on Thursday May 16, 2024 by Dow Jones
7:33AM ET on Thursday May 16, 2024 by Dow Jones
May 15, 2024
Press Release: Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow JonesMereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 457.3M | -12.4x | --- |
Aerovate Therapeutics Inc | 581.1M | -6.7x | --- |
Mind Medicine (MindMed) Inc | 584.0M | -2.8x | --- |
Savara Inc | 576.2M | -11.1x | --- |
Third Harmonic Bio Inc | 586.3M | -20.4x | --- |
Altimmune Inc | 570.1M | -5.0x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $457.3M |
|---|---|
Revenue (TTM) | $9.1M |
Shares Outstanding | 140.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-0.27 |
Book Value | $0.63 |
P/E Ratio | -12.4x |
Price/Sales (TTM) | 50.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -444.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
